Thrivent Financial For Lutherans Mirati Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$36.54 - $54.26 $2.26 Million - $3.35 Million	-61,734 Reduced 46.3%	71,599 $2.66 Million
Q4 2022 Feb 08, 2023	BUY	$41.27 - $98.62 $5.5 Million - $13.1 Million	133,333 New	133,333 $6.04 Million
Q2 2021 Aug 19, 2021	SELL	$144.0 - $179.73 $647,280 - $807,886	-4,495 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $109,336 - $152,467	-688 Reduced 13.27%	4,495 $770,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $7,940 - $11,773	49 Added 0.95%	5,183 $1.14 Million
Q3 2020 Nov 10, 2020	BUY	$113.26 - $167.27 $160,715 - $237,356	1,419 Added 38.2%	5,134 $853,000
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $259,232 - $431,720	3,715 New	3,715 $286,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.